Metraipolis › archive › dc_cb1cf651b43a

Real-world treatment outcomes of aflibercept versus bevacizumab for neovascular age-related macular degeneration — Europe PMC PMID:41518379

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41518379
DOI
10.1007/s00417-[numero omesso]-3
License (as archived)
solo-consultazione
Archived
2026-11-06T22:17:51.657Z
SHA-256 of the archived text
17f964fc6399805b1be8263a2f8dc776b1942875a01ec7f65dbad237db909141
Stable URL of this page
https://metraipolis.com/documento/dc_cb1cf651b43a

How to cite

Real-world treatment outcomes of aflibercept versus bevacizumab for neovascular age-related macular degeneration — Europe PMC PMID:41518379 — Europe PMC (en), https://europepmc.org/article/MED/41518379 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cb1cf651b43a (Metraipolis archive dc_cb1cf651b43a, sha256 17f964fc6399805b1be8263a2f8dc776b1942875a01ec7f65dbad237db909141)
BibTeX
@misc{dccb1cf651b43a,
  title = {Real-world treatment outcomes of aflibercept versus bevacizumab for neovascular age-related macular degeneration — Europe PMC PMID:41518379},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41518379},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cb1cf651b43a; sha256 17f964fc6399805b1be8263a2f8dc776b1942875a01ec7f65dbad237db909141},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41518379. Agents can read the archived copy with the MCP tool read_document.